首页 › 慢性淋巴细胞白血病 › 伊利诺伊州 › Chicago
Chicago IL 慢性淋巴细胞白血病临床试验
14项针对 慢性淋巴细胞白血病的研究正在 Chicago及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
招募中3 期
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- 以及另外 1 项
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
招募中3 期
- Northwestern University, Chicago
- University of Illinois, Chicago
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
招募中3 期
- Northwestern University, Chicago
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
招募中1 期
- The David and Etta Jonas Center for Cellular Therapy, Chicago
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
招募中3 期
- Northwestern University, Chicago
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中3 期
- University of Chicago Medical Center, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- Northwestern University, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- University of Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
招募中1/2 期
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- The University of Chicago Medical Center, Chicago
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- Northwestern University, Chicago
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- Northwestern University, Chicago
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
招募中1 期
- Northwestern Memorial Hospital, Chicago
其他城市的 慢性淋巴细胞白血病试验
- Boston, MA31 项研究
- Columbus, OH29 项研究
- Durham, NC28 项研究
- Washington, DC22 项研究
- Seattle, WA22 项研究
- Rochester, MN20 项研究
- New York City, NY20 项研究
- Houston, TX18 项研究
- Baldwin Park, CA18 项研究
- Cincinnati, OH15 项研究
- Milwaukee, WI15 项研究
- Nashville, TN13 项研究
Chicago的其他研究
- 乳腺癌59 项研究
- 非小细胞肺癌59 项研究
- 癌症（所有类型）51 项研究
- 前列腺癌45 项研究
- 肺癌43 项研究
- 转移性癌症42 项研究
- 肥胖症40 项研究
- 卵巢癌36 项研究
- 结直肠癌32 项研究
- 卒中31 项研究
- 头颈鳞状细胞癌29 项研究
- 超重29 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。